1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,500 | 10,600 | 18.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | AgomAb Therapeutics NV: Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study | 124 | GlobeNewswire (Europe) | -- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high... ► Artikel lesen | |
| 11.09. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 11.09. | Agomab: Aktionäre genehmigen neue Verwaltungsratsmitglieder und eine Anpassung der Optionsscheine | 1 | Investing.com Deutsch | ||
| 11.09. | Agomab: Aktionäre stimmen Berufungen in den Verwaltungsrat und Anpassung von Optionsscheinen zu | 1 | Investing.com Deutsch | ||
| AGOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.09. | Agomab shareholders approve board appointments, warrant adjustment | 1 | Investing.com | ||
| 11.09. | AgomAb Therapeutics NV: Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors | 332 | GlobeNewswire (Europe) | Antwerp, Belgium, September 11, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced... ► Artikel lesen | |
| 25.08. | This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday | 1 | Benzinga.com | ||
| 25.08. | Piper Sandler initiates Agomab stock with Overweight rating | 3 | Investing.com | ||
| 25.08. | XFRA NEW INSTRUMENTS AVAILABLE ON 25.08.2026 | 530 | Xetra Newsboard | The following instruments on XETRA do have their first trading 25.08.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 25.08.2026
Aktien
1 US00860C1027 AgomAb Therapeutics... ► Artikel lesen | |
| 10.08. | Agomab proposes two board members for shareholder vote | 1 | Investing.com | ||
| 10.08. | Agomab proposes two new board members, sets shareholder vote | 1 | Investing.com | ||
| 10.08. | AgomAb Therapeutics NV: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors | 172 | GlobeNewswire (Europe) | Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced... ► Artikel lesen | |
| 23.07. | B.Riley initiates Agomab Therapeutics stock with buy rating | 1 | Investing.com | ||
| 23.06. | Agomab gibt Design für Phase-2b-Studie zu Morbus-Crohn-Medikament bekannt | 4 | Investing.com Deutsch | ||
| 23.06. | Agomab Therapeutics Aligns With FDA On Design Of Phase 2b NOV-ERA Study With Ontunisertib | 1 | Benzinga.com | ||
| 23.06. | Agomab announces Phase 2b study design for Crohn's disease drug | 1 | Investing.com | ||
| 23.06. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.06. | AgomAb Therapeutics NV: Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease | 567 | GlobeNewswire (Europe) | -- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation... ► Artikel lesen | |
| 22.06. | H.C. Wainwright initiates Agomab stock coverage with buy rating | 1 | Investing.com | ||
| 27.05. | Agomab Therapeutics NV - 6-K, Report of foreign issuer | 1 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,664 | +1,96 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| ARBUTUS BIOPHARMA | 4,320 | -0,92 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| CARDIFF ONCOLOGY | 1,120 | -6,43 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| ALDEYRA | 1,170 | 0,00 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 17,550 | +2,18 % | Denali Therapeutics: Markteinführung von Avlayah gewinnt an Fahrt | ||
| ABCELLERA BIOLOGICS | 10,920 | 0,00 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 24,770 | -0,56 % | Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ | Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity... ► Artikel lesen | |
| AC IMMUNE | 2,300 | -0,22 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,112 | -4,39 % | Coherus auf Morgan Stanley Konferenz: Onkologie-Strategie gewinnt an Dynamik | ||
| CYTOMX THERAPEUTICS | 2,420 | +0,88 % | CytomX auf Morgan Stanley Konferenz: Strategie für fortgeschrittenes Kolorektalkarzinom im Fokus | ||
| CYBIN | 11,120 | +3,35 % | Helus Pharma auf Morgan Stanley Konferenz: Strategie zielt auf breiteren Depressionsmarkt | ||
| AGENUS | 6,400 | -6,57 % | Agenus Inc.: Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,040 | +0,06 % | Arcturus to present Phase 2 data for OTC deficiency treatment |
Das Unternehmen AGOMAB THERAPEUTICS NV ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 10,000 Euro und damit -5,66 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AGOMAB THERAPEUTICS NV ADR finden Sie auf Wallstreet Online.